Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins and mRNA into Freshly Isolated Primary Mouse Hepatocytes
June 2nd, 2022
2.8K views
This protocol describes techniques for isolating primary mouse hepatocytes from the liver and electroporating CRISPR-Cas9 as ribonucleoproteins and mRNA to disrupt a therapeutic target gene associated with an inherited metabolic disease of the liver. The methods described result in high viability and high levels of gene modification after electroporation.
Overview
This protocol outlines a straightforward and reproducible method for isolating primary mouse hepatocytes and utilizing CRISPR-Cas9 for gene editing. The approach facilitates the generation of in vitro and in vivo disease models by disrupting target genes associated with liver metabolic diseases.
Key Study Components
Area of Science
- Gene editing
- Hepatocyte isolation
- Metabolic disease modeling
Background
- Primary mouse hepatocytes are crucial for studying liver functions and diseases.
- CRISPR-Cas9 technology allows for precise gene modifications.
- Isolated hepatocytes can be used for therapeutic applications.
- Challenges exist in the technical aspects of the isolation and editing processes.
Purpose of Study
- To provide a reliable method for gene editing in primary mouse hepatocytes.
- To enable the creation of disease models for inherited metabolic disorders.
- To facilitate potential therapeutic strategies through cell transplantation.
Methods Used
- Isolation of primary mouse hepatocytes from the liver.
- Electroporation of CRISPR-Cas9 ribonucleoproteins and mRNA.
- Assessment of cell viability and gene modification efficiency.
- Demonstration of techniques by experienced researchers.
Main Results
- High viability of isolated hepatocytes post-electroporation.
- Significant levels of gene modification achieved.
- Successful demonstration of the procedure by trained personnel.
- Potential for future applications in patient-specific therapies.
Conclusions
- The described techniques are effective for gene editing in hepatocytes.
- They hold promise for advancing research in metabolic liver diseases.
- Careful adherence to protocols is essential for success.
Frequently Asked Questions
What is the main advantage of this technique?
It is an easy, fast, and reproducible approach for gene editing in primary mouse hepatocytes.
Who demonstrates the procedures?
Tina Parker and Ilayda Ates demonstrate the liver perfusion and hepatocyte isolation, while Callie Stuart demonstrates the electroporation.
What challenges might inexperienced researchers face?
They may struggle with cannulation and maintaining catheter stability during perfusion.
What should users do before starting the procedure?
Users are advised to carefully read and practice the procedure and troubleshooting methods.
What is the potential application of this technique?
It may allow for the transplantation of gene-edited hepatocytes back into patients.
What is the significance of high viability in hepatocytes?
High viability indicates successful isolation and preparation for further experimentation.
Executive Industry Relevance
Efficient gene editing in primary mouse hepatocytes via electroporation of Cas9 RNPs and mRNA enables rapid generation of disease-relevant liver models for early-stage target validation. This workflow supports predictive confidence in gene function studies and accelerates the creation of preclinical models for inherited metabolic liver diseases. High transfection efficiency and quantifiable editing outcomes position this protocol as a strategic asset for translational research and portfolio triage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of therapeutic gene function in primary hepatocytes.
- Supports mechanistic de-risking by quantifying on-target gene editing efficiency.
- Facilitates rapid generation of disease-relevant in vitro and in vivo models.
- Provides a reproducible platform for functional target validation in liver biology.
Screening & Assay Development
- Delivers high-purity, viable hepatocytes suitable for downstream screening workflows.
- Standardizes electroporation-mediated delivery for reproducible gene editing outcomes.
- Enables quantitative assessment of editing via GFP expression and indel analysis.
- Supports assay development for functional and viability readouts post-editing.
Translational & Preclinical Research
- Aligns with generation of mouse models for human liver genetic diseases.
- Maintains functional hepatocyte viability for transplantation and engraftment studies.
- Provides continuity from gene editing to preclinical validation of therapeutic hypotheses.
- Enables biomarker analysis such as albumin secretion for translational relevance.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical model generation, supporting workflows from hypothesis testing to in vivo validation.
- Discovery Biology: Quantifies gene editing efficiency and functional impact in primary hepatocytes.
- Screening: Provides standardized, high-efficiency transfection for assay-ready cells.
- Analytics: Enables measurement of GFP positivity, indel frequency, and functional biomarkers.
- Translational Research: Supports creation of disease models and transplantation studies for preclinical continuity.
- Enterprise Reuse: Offers a scalable, reproducible platform for gene editing across liver disease targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in gene function and target validation.
- Operational Value: Delivers standardized, high-yield hepatocyte isolation and editing workflows.
- Strategic Value: Accelerates go/no-go decisions for liver disease targets and models.
- Portfolio Impact: Enables risk-adjusted prioritization of gene targets and disease models.
Implementation Considerations
- Requires technical expertise in liver perfusion and electroporation procedures.
- Needs access to electroporation instrumentation and cell culture infrastructure.
- Demands cross-team standardization for reproducibility and troubleshooting.
- Adaptable to various gene targets and disease-relevant hepatocyte models.
- Dependent on careful cannulation and perfusion for optimal cell yield and viability.
Biopharma FAQs
Why does null hypothesis testing matter for Cas9 gene editing in hepatocytes?
Null hypothesis testing enables objective assessment of whether Cas9-mediated editing produces statistically significant changes in gene function or biomarker output, supporting robust target validation in primary hepatocytes.
How does independent variable isolation fit the electroporation workflow?
Isolating variables such as RNP versus mRNA delivery allows teams to directly compare editing efficiency and viability, informing optimization and mechanistic de-risking in the discovery pipeline.
What do quantitative GFP and indel measurements enable in this protocol?
Quantitative GFP positivity and indel frequency provide actionable metrics for transfection efficiency and on-target editing, enabling data-driven decisions for downstream model development and screening.
Why are replication requirements critical for cross-functional hepatocyte editing studies?
Replication ensures reproducibility of editing efficiency and viability outcomes, facilitating reliable data sharing and collaboration across discovery, screening, and translational research teams.
What statistical analysis capabilities are required before implementing gene editing readouts?
Teams must apply statistical methods to compare editing efficiencies, viability, and biomarker outputs across conditions, ensuring that observed effects are robust and suitable for portfolio decision-making.
